

The expanding scope of DNA sequencing

Jay Shendure¹ & Erez Lieberman Aiden^{2–4}

In just seven years, next-generation technologies have reduced the cost and increased the speed of DNA sequencing by four orders of magnitude, and experiments requiring many millions of sequencing reads are now routine. In research, sequencing is being applied not only to assemble genomes and to investigate the genetic basis of human disease, but also to explore myriad phenomena in organismic and cellular biology. In the clinic, the utility of sequence data is being intensively evaluated in diverse contexts, including reproductive medicine, oncology and infectious disease. A recurrent theme in the development of new sequencing applications is the creative ‘recombination’ of existing experimental building blocks. However, there remain many potentially high-impact applications of next-generation DNA sequencing that are not yet fully realized.

The cost of DNA sequencing has plummeted since 2005 (refs. 1,2), from \$1,000 per megabase down to a mere ten cents per megabase^{3,4}. Next-generation technologies have also commoditized high-throughput DNA sequencing and rendered it broadly accessible to individual investigators outside of genome centers^{3,5} (J.S. and colleagues). For many applications, the cost of sequencing is already negligible in comparison to the costs of sample acquisition, library preparation and/or postsequencing data analysis (Box 1). For very large-scale applications, such as whole-genome sequencing of samples for entire cohort studies, the cost of sequencing remains substantial but only because we are undertaking projects that were out of reach just a few years ago in terms of scale and comprehensiveness.

As a consequence of these dramatic shifts in cost and accessibility, applications of DNA sequencing have proliferated (Table 1). Until 2005, the primary application of high-throughput DNA sequencing was to assemble reference genomes for humans and other high priority species. Today, sequencing has an increasingly fundamental role in the genetic analysis of human disease and model organism phenotypes as well as in addressing basic questions in organismic and cellular biology. For many researchers, the state of sequencing technology (for example, cost per genome, read-length constraints and so on) is already profoundly influencing the design and scope of their experiments. We predict that much of the agenda of biology in the coming decade will be driven in large part by the scientific opportunities afforded by next-generation DNA sequencing technologies. Understanding current applications of sequencing, the structure of sequencing experiments and principles for devising new sequencing applications will be useful for researchers seeking to effectively harness these opportunities.

Details of next-generation DNA sequencing technologies are well described in recent reviews^{3,5–8}. In this Review, we assume that future DNA sequencing technologies will yield large quantities of accurate DNA sequence at extremely low cost. This view does not seek to downplay the importance of the technical challenges particular to each sequencing platform (Table 2) or to suggest that DNA sequencing is a solved problem. There remains ample room for improvement with respect to almost every technical parameter. We also do not suggest that sequencers are interchangeable: specific applications are best supported by different platforms. Indeed, the next-generation sequencing market recently has begun to differentiate into ‘high-throughput’ instruments, ‘long-read’ instruments and ‘bench-top’ instruments (Box 1 and Table 2), a trend that is likely to continue.

In this Review, we consider applications that have been made possible by the recent advances in DNA sequencing technology and provide guidance for experimental design and the development of new sequencing applications. First, we propose a general framework for thinking about applications of next-generation DNA sequencing and discuss the most exciting applications and salient challenges in each area. Second, we identify building blocks that are common to many sequencing-based experimental strategies and consider how best to incorporate sequencing technologies into a variety of experimental approaches.

Applications of sequencing

The recent advances in sequencing technology are enabling researchers to consider questions at the level of the species, the organism, the cell and the biological mechanisms in a cell. Here we review applications of next-generation DNA sequencing at each of these levels (summarized in Fig. 1).

Sequencing the genome of a species. Key milestones in genome sequencing include the Human Genome Project as well as other early projects directed at assembling reference genomes for prominent model organisms such as yeast, worm, fly and mouse. Subsequent projects have emphasized species most likely to inform evolutionary studies through comparative analysis—for example, the low-coverage sequencing of 29 mammalian genomes to broadly identify sequences under functional constraint⁹. As costs plummet, ambitions have skyrocketed: for instance,

¹Department of Genome Sciences, University of Washington, Seattle, Washington, USA. ²Laboratory at Large, School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA. ³Broad Institute of Harvard and MIT, Harvard University, Cambridge, Massachusetts, USA.

⁴Harvard Society of Fellows, Harvard University, Cambridge, Massachusetts, USA. Correspondence should be addressed to E.L.A. (erez@erez.com) or J.S. (shendure@uw.edu).

Received 29 May 2012; accepted 15 October 2012; published online 8 November 2012; doi:10.1038/2421




Figure 1 Where we are headed: a road map of sequencing science. The earliest sequencing projects focused on creating 'reference' genomes for individual species of interest. With new technologies, such projects can now be taken on for entire taxa, even when some of their members are extinct (top left). Next-generation sequencing is also enabling the study of biological systems at ever-finer scales. For example, we can explore genetic variation between individual members of a single species (top center), and the genetic and epigenetic differences between the cells of a single individual (top right). Sequencing can also provide a window into diverse processes in cells, including all of the phenomena shown (bottom).

generation' methods of obtaining contiguity information at different scales. This might be as simple as including data from alternative sequencing platforms with a higher cost-per-base but substantially longer read lengths (Table 2 and Box 1). It could also include additional sources of contiguity information at a diversity of scales, such as long-distance mate-paired reads, hierarchical (that is, clone by clone) sequencing, dilution-pool sequencing, optical sequencing and genetic maps. As sequencing technologies continue to mature,

a truly complete reference assembly of the human genome will be an increasingly realistic ambition (Table 3).

Cataloging variation between individuals of a species. Genetic variation within a species underlies a substantial fraction of phenotypic variation—for example, the genetic contribution to human disease risk. Fortunately, using sequencing to identify genetic variation between individuals of the same species is considerably easier than assembling a reference genome for the species in the first place, as it only requires the mapping of reads to a reference assembly while allowing for differences owing to polymorphisms or sequencing errors^{1,14}. With sufficient coverage, one can then identify certain types of genetic variation with high sensitivity and specificity, for example, single-nucleotide polymorphisms¹⁵.

One challenge for the future will be to develop techniques that enable more complete maps of genetic variation. For example, current methods have limited sensitivity and specificity for detecting small insertions and deletions, tandem repeat expansions, transposition events, copy-number variation, copy-neutral rearrangements and all types of variation within

the Genome 10K project aims to produce a *de novo* assembly for each of over 10,000 vertebrate species¹⁰.

Nevertheless, the *de novo* sequencing of a complete genome (that is, a gapless, errorless, end-to-end assembly) is far from routine. New technologies are required to facilitate the sequencing of repetitive genomic regions (including transposons, satellite sequences, segmental duplications, ribosomal sequences and the like), which have largely confounded sequencing technologies to date. These regions are difficult to sequence even in relatively small genomes, such as that of *Saccharomyces cerevisiae*. For example, the current 12-Mb genome assembly of *S. cerevisiae* omits the 1-megabase rDNA locus.

Repetitive regions are particularly challenging for sequencing because identical reads may be generated from multiple locations in the genome. Despite advances in assembly algorithms^{11,12}, the quality of *de novo* genome assemblies based purely on shotgun reads continues to fall short of the assemblies that can be achieved by hierarchical, clone-based Sanger sequencing¹³. It is unlikely that this gap can be overcome simply by increasing the amount of sequence data entering the assemblies. Instead, what are required are 'next-

Box 1 'Rate limiters' of next-generation DNA sequencing experiments

Until recently, the act of acquiring high-throughput molecular data (for example, DNA sequencing or DNA microarrays) was the primary cost associated with many experiments in genomics (for example, genome assembly, expression analysis and so on). For some projects, the emergence of next-generation sequencing has simply increased ambitions, such that DNA sequencing costs remain dominant. However, for most experiments, other 'rate limiters' are an increasing fraction of the overall cost and effort. These include the following: first, the cost of generating, acquiring and/or storing samples; second, the costs of constructing and indexing fragment libraries; third, the costs of building and maintaining infrastructure for

large-scale data analysis, storage, exchange and deposition to public repositories; fourth, the time and labor costs of executing on both routine (for example, read mapping) and specialized (for example, data interpretation) tasks in large-scale data analysis; fifth, the costs of training personnel for the experimental and analytical skill sets associated with next-generation DNA sequencing; sixth, the costs associated with transient or persistent mismatches between the local capacity and local demand for next-generation DNA sequencing; and finally, for clinical samples, the costs associated with phenotyping subjects, obtaining consent from subjects and complying with regulations for working with human subjects.

Table 1 Applications of next-generation DNA sequencing

Method	Sequencing to determine:	Example reference	'Subway' route as defined in Figure 3
DNA-Seq	A genome sequence	57	Comparison, 'anatomic' (isolation by anatomic site), flow cytometry, DNA extraction, mechanical shearing, adaptor ligation, PCR and sequencing
Targeted DNA-Seq	A subset of a genome (for example, an exome)	20	Comparison, cell culture, DNA extraction, mechanical shearing, adaptor ligation, PCR, hybridization capture, PCR and sequencing
Methyl-Seq	Sites of DNA methylation, genome-wide	34	Perturbation, genetic manipulation, cell culture, DNA extraction, mechanical shearing, adaptor ligation, bisulfite conversion, PCR and sequencing
Targeted methyl-Seq	DNA methylation in a subset of the genome	129	Comparison, cell culture, DNA extraction, bisulfite conversion, molecular inversion probe capture, circularization, PCR and sequencing
DNase-Seq, Sono-Seq and FAIRE-Seq	Active regulatory chromatin (that is, nucleosome-depleted)	113	Perturbation, cell culture, nucleus extraction, DNase I digestion, DNA extraction, adaptor ligation, PCR and sequencing
MAINE-Seq	Histone-bound DNA (nucleosome positioning)	130	Comparison, cell culture, MNase I digestion, DNA extraction, adaptor ligation, PCR and sequencing
ChIP-Seq	Protein-DNA interactions (using chromatin immunoprecipitation)	131	Comparison, 'anatomic', cell culture, cross-linking, mechanical shearing, immunoprecipitation, DNA extraction, adaptor ligation, PCR and sequencing
RIP-Seq, CLIP-Seq, HITS-CLIP	Protein-RNA interactions	46	Variation, cross-linking, 'anatomic', RNase digestion, immunoprecipitation, RNA extraction, adaptor ligation, reverse transcription, PCR and sequencing
RNA-Seq	RNA (that is, the transcriptome)	39	Comparison, 'anatomic', RNA extraction, poly(A) selection, chemical fragmentation, reverse transcription, second-strand synthesis, adaptor ligation, PCR and sequencing
FRT-Seq	Amplification-free, strand-specific transcriptome sequencing	119	Comparison, 'anatomic', RNA extraction, poly(A) selection, chemical fragmentation, adaptor ligation, reverse transcription and sequencing
NET-Seq	Nascent transcription	41	Perturbation, genetic manipulation, cell culture, immunoprecipitation, RNA extraction, adaptor ligation, reverse transcription, circularization, PCR and sequencing
Hi-C	Three-dimensional genome structure	71	Comparison, cell culture, cross-linking, proximity ligation, mechanical shearing, affinity purification, adaptor ligation, PCR and sequencing
Chia-PET	Long-range interactions mediated by a protein	73	Perturbation, cell culture, cross-linking, mechanical shearing, immunoprecipitation, proximity ligation, affinity purification, adaptor ligation, PCR and sequencing
Ribo-Seq	Ribosome-protected mRNA fragments (that is, active translation)	48	Comparison, cell culture, RNase digestion, ribosome purification, RNA extraction, adaptor ligation, reverse transcription, rRNA depletion, circularization, PCR and sequencing
TRAP	Genetically targeted purification of poly-somal mRNAs	132	Comparison, genetic manipulation, 'anatomic', cross-linking, affinity purification, RNA extraction, poly(A) selection, reverse transcription, second-strand synthesis, adaptor ligation, PCR and sequencing
PARS	Parallel analysis of RNA structure	42	Comparison, cell culture, RNA extraction, poly(A) selection, RNase digestion, chemical fragmentation, adaptor ligation, reverse transcription, PCR and sequencing
Synthetic saturation mutagenesis	Functional consequences of genetic variation	93	Variation, genetic manipulation, barcoding, RNA extraction, reverse transcription, PCR and sequencing
Immuno-Seq	The B-cell and T-cell repertoires	86	Perturbation, 'anatomic', DNA extraction, PCR and sequencing
Deep protein mutagenesis	Protein binding activity of synthetic peptide libraries or variants	95	Variation, genetic manipulation, phage display, <i>in vitro</i> competitive binding, DNA extraction, PCR and sequencing
PhIT-Seq	Relative fitness of cells containing disruptive insertions in diverse genes	92	Variation, genetic manipulation, cell culture, competitive growth, linear amplification, adaptor ligation, PCR and sequencing

FAIRE-seq, formaldehyde-assisted isolation of regulatory elements–sequencing. MAINE-Seq, MNase-assisted isolation of nucleosomes–sequencing; RIP-Seq, RNA-binding protein immunoprecipitation–sequencing; CLIP-Seq, cross-linking immunoprecipitation–sequencing; HITS-CLIP, high-throughput sequencing of RNA isolated by cross-linking immunoprecipitation; FRT-Seq, on-flowcell reverse transcription–sequencing. NET-Seq, native elongating transcript sequencing. TRAP, translating ribosome affinity purification. PhIT-Seq, phenotypic interrogation via tag sequencing.

structurally complex regions of a genome. A separate aspect of completeness, effectively ignored by conventional shotgun genome sequencing, is haplotype information, for example, the combinations of alleles present on the same chromosome in a diploid human genome. Several methods have recently enabled the ascertainment of haplotypes at a genome-wide scale, albeit only locally^{16,17} or sparsely^{18,19}. Combinations of these methods, or entirely new technologies, will be required fully resolve haplotypes in nonhaploid genomes.

Another challenge is how best to use sequencing to understand the genetic basis of human disease. Genome sequencing and exome sequencing (that is, the targeted sequencing of the ~1% of the human genome that is protein-coding) have substantially accelerated the determination of the genetic basis for single-gene (Mendelian) disorders^{20,21} and are being used to identify *de novo* mutations that may be risk factors for neuropsychiatric disorders such as intellectual disability²², autism²³ (J.S. and colleagues) and schizophrenia²⁴. For complex traits and common diseases, genome-wide association studies have already identified the most common risk alleles. Ongoing, sequencing-based studies may clarify the contribution of rare variants, common variants with small

effect sizes and epistatic interactions to the so-called 'missing heritability'²⁵. However, these are likely to require enormous disease cohorts so as to have adequate statistical power.

In a clinical setting, many barriers still prevent the routine use of genome sequencing to inform patient care. Notably, the utility of genomic information to provide a personalized, asymptomatic prognosis for common diseases is inherently limited (exemplified by the simple fact that monozygotic twins do not usually die of the same disease)^{26,27}. Instead, genome sequencing may be most useful for diagnosing rare, Mendelian disorders where the mutations are highly penetrant and thus more readily interpreted. For example, there are already case reports where exome or genome sequencing has led to a clear diagnosis of a known Mendelian disorder in a patient for whom that diagnosis had not been suspected, leading to substantial and sometimes life-saving changes in clinical management^{21,28,29}.

Clinical sequencing of human genomes may also prove highly impactful in the context of reproductive health, as about 1% of new births are affected by a Mendelian disorder requiring specialized medical attention. Preconception screening of carrier status across hundreds of severe

Table 2 Next-generation DNA sequencing instruments

	Cost per base ^a	Read length (bp) ^b	Speed	Capital cost ^c
Minimum cost per base				
Complete Genomics	Low	Short	3 months	None (service)
HiSeq 2000 (Illumina)	Low	Mid	8 days	+++++++
SOLiD 5500xl (Life Technologies)	Low	Short	8 days	+++
Maximum read length				
454 GS FLX+ (Roche)	High	Long	1 day	+++++
RS (Pacific Biosciences)	High	Very long	<1 day	+++++++
Maximum speed, minimum capital cost and minimum footprint				
454 GS Junior (Roche)	High	Mid	<1 day	+
Ion Torrent PGM (Life Technologies)	Mid	Mid	<1 day	+
MiSeq (Illumina)	Mid	Long	1 day	+
Combined prioritization of speed and throughput				
Ion Torrent Proton (Life Technologies)	Low	Mid	<1 day	++
HiSeq 2500 (Illumina)	Low	Mid	2 days	+++++++

^aLow' is < \$0.10 per megabase, 'mid' is in-between and 'high' is > \$1 per megabase. ^b'Short' is < 200 bp, 'mid' is 200–400 bp, 'long' is > 400 bp and 'very long' is > 1,000 bp. ^cEach "+" corresponds to ~\$100,000. We list only commercialized instruments that can be purchased and for which performance data are publicly available (as opposed to a comprehensive list of companies developing next-generation sequencing technologies). The categorizations refer to the aspect of sequencing performance to which the technology and/or its implementation in a specific instrument are primarily geared. These estimates were made at the time of publication, and the pace at which the field is moving makes it likely that they will be quickly outdated.

recessive disorders has been demonstrated and may eventually become routine³⁰. After conception, an appreciable fraction of maternal cell-free DNA during pregnancy can be derived from the fetus. As such, aneuploidies can now be noninvasively detected by next-generation sequencing^{31,32}, and clinical tests implementing this are gaining rapid adoption. Furthermore, by combining haplotype-resolved parental genome sequencing and maternal cell-free DNA sequencing, we have recently demonstrated noninvasive, whole-genome sequencing of a human fetus using samples obtained noninvasively from parents in the second trimester³³ (J.S. and colleagues). Although improvements with respect to cost, accuracy and variant interpretation are necessary, such methods may eventually enable the noninvasive, prenatal diagnosis of many, if not most, Mendelian disorders.

Characterizing differences between cells within an individual. Recent studies have applied sequencing to reveal differences in regulatory state between different cell types in an organism, the somatic genetic variation that defines the immune repertoire, somatic differences between the genomes of cancerous and normal cells, and the microorganisms that colonize the human body.

Cell-to-cell differences in the regulatory state of a genome underlie differences in transcription, translation and cellular phenotype. Epigenetics traditionally refers to the study of biochemical changes in the immediate vicinity of DNA, including modifications of the DNA itself (for example, DNA methylation) and modifications of the histone proteins that package DNA into chromatin. Such epigenetic marks, as well as chromatin accessibility and transcription factor binding, directly involve DNA and are thus readily detected using sequencing-based assays^{34–37}. Current challenges in applying sequencing to query the epigenome include specificity (for example, producing effective antibodies for each histone modification or transcription factor), adapting protocols to very low amounts of starting material and measuring the dynamics of epigenetic regulation rather than obtaining static snapshots³⁸. Transcriptional processes have been interrogated in exquisite detail by sequencing-based methods for profiling steady-state expression³⁹, allele-specific expression⁴⁰, nascent transcription⁴¹, secondary structure formation⁴², alternative splicing⁴³, RNA editing⁴⁴, protein binding^{45,46} and degradation⁴⁷. Translation of mRNA into protein can also be monitored via ribosomal profiling⁴⁸. However, the methodological

equivalent of massively parallel sequencing for amino acid polymers has yet to be developed (Table 3). Possible solutions are analogous to next-generation DNA sequencing technologies, for example, nanopores⁴⁹ or identifying and counting single protein molecules spread on a two-dimensional surface⁵⁰.

Immunogenomics uses massively parallel sequencing to characterize complex T-cell receptor and B-cell receptor repertoires in samples from individuals, with high depth and resolution^{51–54}. Sequencing immune repertoires might make it possible to identify the acute response to diseases or malignancies, to gauge the status of the immune system in the context of immunodeficiency, transplantation or normal aging and to track malignancies of the hematopoietic system itself. Furthermore, profiling immune memory could identify markers of past exposures and successful vaccinations⁵⁵. To achieve their potential, such methods must evolve toward reliably quantifying

the abundances of an extraordinarily diverse population of immune receptor genes. Technical challenges to achieving this include the enormous dynamic range of the immune repertoire as well as the fact that the two chains of individual T-cell receptors and B-cell receptors are unlinked in the genome and transcriptome.

Cancer cells exhibit pronounced genomic instability⁵⁶. Differences between an organism's genome and a derivative cancer genome are readily determined by sequencing, albeit with the previously mentioned difficulties in detecting many relevant types of variation. Sequencing-based characterization of cancer genomes, epigenomes and transcriptomes is already informing the basic biology of specific cancer types, and the resulting insights may eventually provide a more powerful classification of human cancers than anatomy or histology. However, there is also remarkable heterogeneity among tumors ostensibly of the same type, and fully understanding the genetic basis of cancer is likely to require the characterization of extremely large numbers of cancer samples. Nonetheless, there is considerable enthusiasm about the use of genomic information to directly facilitate therapeutic decision-making for cancer patients⁵⁷. For example, there are several reports of whole-genome sequencing of tumor DNA from individual patients yielding information that has altered clinical decisions^{58,59}. Deep sequencing may also enable noninvasive cancer-screening methods, for instance, by examining circulating tumor cells⁶⁰ or stool⁶¹. Detailed dissection of genetic heterogeneity in tumors through techniques such as 'single-nucleus sequencing' coupled with lineage analysis⁶² may also lead to a better understanding of cancer evolution as well as to improved diagnostics and prognostics. Of note, the needs of clinical laboratories in this area, for example, those seeking to implement next-generation sequencing of actionable cancer genes, are driving the market to offer instruments particularly geared to their requirements, for example, the development of 'bench-top' sequencers (Table 2 and Box 1).

Sequencing-based surveys of microbial communities (including shotgun metagenome sequencing and profiling of signature 16S rDNA), both in the human body^{63,64} and in environmental niches ranging from whale falls to acid mines, are overturning our world view of the number and breadth of species associated with humans and the environment. Genome sequencing of bacterial^{65,66} and viral⁶⁷ pathogens (including of viral quasi-species⁶⁸) has been used to detect the microorganisms responsible for disease outbreaks as well as to track the emergence and

spread of antibiotic resistance. It is likely that these tools will become an increasingly important part of public health efforts in the coming decades. A key challenge for the future is to obtain a better understanding of the relationship between microbiome composition and human disease. For instance, obesity is associated with less microbial diversity in the gut microbiome, but the mechanisms underlying this association are not yet well-understood⁶⁹. Although improved sequencing methods will enable more accurate quantification and content-determination of such complex microbial populations, new types of experiments (for example, perturbation instead of comparison; see below) may be required to study causal relationships.

Using sequencing to understand cellular mechanisms. Many of the techniques described above in the context of identifying cell-to-cell differences in regulatory state, when applied to a single cell or a single cell type, can be used to explore the underlying cellular circuitry (for example, chromatin immunoprecipitation with subsequent high-throughput sequence analysis (ChIP-Seq) for protein-DNA interactions, high-throughput RNA sequencing (RNA-Seq) for transcription and 'Ribo-Seq' for translation) or even molecular biophysics (for example, parallel analysis of RNA structure (PARS)⁴²). In addition, new applications are emerging that are especially suited to this goal. For instance, methods based on *in vivo* proximity ligation, first used almost 20 years ago in the so-called nuclear ligation assay⁷⁰, enable the exploration of the spatial arrangement of cellular components, for example, the proximity between genomic loci. Considerable improvements have been made to this technology, and recently, global mapping of DNA-DNA interactions using proximity ligation coupled with deep sequencing (Hi-C) has shed light on how the genome packs inside the nucleus (E.L.A. and colleagues⁷¹; J.S. and colleagues⁷²). A related technique, chromatin interaction analysis by paired-end tag sequencing (ChIA-PET)⁷³, focuses on the global interactions of specific transcription factors and may help shed light on the physical basis of enhancer activity.

Despite these challenges, such methods make sequencing a viable option for many research questions that would previously have required microscopy, for instance, the hypothesis that genome breakpoints in cancer tissue are spatially co-localized before rearrangement⁷⁴. Cellular components can also be tracked over time, for example, by sequencing-based interrogation of the temporal pattern of DNA replication⁷⁵.

Eventually, new techniques may enable tracking of cellular dynamics through both space and time simultaneously (Table 3, *in situ* sequencing). Taken together, these methods highlight the dramatic transition that sequencing has undergone in biology: a technology originally designed to study genetics is rapidly becoming a mainstay of cell biology and biophysics.

Design of sequencing experiments

Wilhelm von Humboldt described language as a system that makes 'infinite use of finite means': despite a relatively small number of words and combinatorial rules, it is possible to express an infinite range of ideas. The space of contemporary sequencing applications has developed along similar lines: a relatively small number of experimental designs and protocols find use in a wide array of applications, and new applications often emerge by mixing and matching these building blocks. Our goal below is to capture the diversity of these techniques, to describe how they are combined in existing applications and to suggest how they might be combined to create new techniques.

We discuss sequencing experiments at two levels: experimental designs, which describe how biological systems are transformed into a collection of cell populations to be analyzed at the molecular level; and sequencing protocols, which describe the molecular steps by which specific information in these cells is captured and transformed into a population of adaptor-flanked DNA fragments for sequencing.

Below we discuss three approaches to experimental design (comparison, perturbation and variation) (Fig. 2a).

Comparison. This kind of study compares evolutionarily, developmentally, spatially, temporally or otherwise related samples to explore the differences that are present in natural environments. For example, comparison has been applied to identify differences between organisms or cell types⁷⁶, to study spatiotemporal changes during development⁷⁷ and to explore variation in cells⁷⁸ or individuals⁷⁹ that are presumed to be genetically identical.

One example of such a design is the comparison of phylogenetically related species, that is, comparative genomics. With the development of paleogenomic techniques, comparative genomics has even been extended to include species that are extinct⁸⁰. Population genetics is essentially the comparison of patterns of natural variation between




Figure 2 Structure of sequencing experiments. (a) Experimental designs describe the ways in which biological systems are transformed into a collection of cell populations to be analyzed at the molecular level. (b) Sequencing protocols are the molecular steps by which specific information in these cells is captured and transformed into a population of adaptor-flanked DNA fragments for sequencing. Future applications of sequencing may arise through new combinations of steps, the introduction of new steps or entirely new approaches to sequencing.

individuals in a species⁸¹. Similarly, the application of sequencing to identify genetic variations associated with disease-affected individuals (for germ-line variation) or cells (for somatic mutations) is also a comparative design. An additional paradigm, which might be termed comparative epigenetics, primarily studies epigenetic differences between related cell types. More recently, the comparative study of geographically related species, that is, natural ecosystems, has been gaining popularity. This 'metagenomic' approach includes the study of diverse ecological niches⁸² as well as site-to-site or individual-to-individual variation in the microbiomes associated with human body^{63,64,69}.

The comparative strategy has been particularly common among large-scale consortia, for example, the International Human Genome Consortium, the HapMap project, Encyclopedia of DNA Elements (ENCODE), modENCODE, the 1000 Genomes project, the International Cancer Genome Consortium and the Human Microbiome project. These efforts have produced crucial infrastructure for genomics, for example, detailed genetic and epigenetic maps of the most common organism and cell models.

Advantages of comparative studies include that they exploit naturally occurring differences that cannot necessarily be generated by other means (for example, human genetic variation) and that these same natural differences may be of primary interest (for example, the contribution of human genetic variation to disease risk). However, this is also a constraint, as there is likely much variation or potential variation that is not readily manifest in accessible, naturally occurring samples. Examples include potential genetic variants that are simply not present in a population or cell types that are inaccessible because they occur very early during human development. A second disadvantage is that comparative studies are inherently observational, and therefore it can be difficult to establish causality. An example is genome-wide association studies, where linkage disequilibrium between nearby alleles makes it extremely difficult to specifically determine which genetic variant(s) causally underlie an observed association with a human disease.

Perturbation. In a perturbation experiment, an organism or cell culture is stimulated in a controlled manner (for instance, using heat shock), and the response is measured, with the aim being to more fully expose the underlying cellular program. In the short term, this response usually takes the form of changes to various aspects of cell state (for example, alterations in signaling cascades, epigenetic regulation or gene expression)—all of which are molecular phenotypes that can be interrogated by sequencing. When the perturbed cells are dividing, genetic changes and selection may occur, that is, experimental or directed evolution^{83,84}. For example, experimental evolution accompanied by whole-genome sequencing can be used to explore the mechanisms by which pathogens or tumors become drug-resistant⁸⁵. In a clinical context, the perturbation might consist of a therapy, where sequencing may be used to gauge the response⁸⁶. Extremely specific perturbations have been achieved through the use of RNA interference-mediated knockdown of a particular gene(s)⁸⁷ and optogenetic controls⁸⁸.

Perturbation studies have the advantage of being truly controlled experiments—that is, comparing an experimental sample to a control sample with the only difference being the presence or absence of a specific perturbation. The use of high-dimensional, sequencing-based readouts for such experiments (for example, RNA-Seq to globally measure transcriptional changes in response to a perturbation) has both advantages and disadvantages. Although the comprehensiveness of the readout means that one is more likely to detect relevant biology in a global, unbiased way, the reality is that one is more often than not awash in such findings and it can be difficult to translate these into a meaningful biological interpretation. However, the solution may simply be more

sophisticated experiments—for example, systematic, large-scale perturbation experiments that enable the *de novo* reconstruction of regulatory networks containing both known and new biology⁸⁹.

Variation. Experimental designs in which the genetic program is directly modified seek to determine how specific functions are encoded by particular sequences. These include, for example, random mutagenesis, which is classically accomplished by a chemical agent (for example, *N*-ethyl-*N*-nitrosourea) or enzymatic process (for example, mutagenic PCR, transposase insertion^{90,91} and retroviral gene traps⁹²). More recently, DNA synthesis has been applied to introduce structured^{93,94} or unstructured^{95,96} patterns of dense mutagenesis in sequences of interest.

An alternative to random mutagenesis is to engineer targeted genetic changes. Gene knockouts and knock-ins, viral transformation, and transfection by expression vectors are classic but still evolving techniques that remain extraordinarily powerful. The seminal discovery of cellular reprogramming, in which one cell type can be transformed into another (for example, via viral transformation⁹⁷; viral, nonintegrating transfection⁹⁸; nonviral, reversible transformation⁹⁹; or episomal transient transfection¹⁰⁰) is a particularly vivid example of the potential of targeted genetic manipulation. Sequencing is not only a powerful tool for monitoring cellular reprogramming and targeted genetic engineering but is also useful for comprehensively identifying the 'off-target' effects of these manipulations.

The manipulation of the genetic program is effectively a very defined type of perturbation, and using sequencing-based readouts for such experiments have the same advantages and disadvantages discussed above. However, a specific advantage of some designs invoking genetic variation is that they allow one to investigate many perturbations in one experiment, for example, genome-wide, random mutagenesis to identify genes in which mutations cause or rescue a specific phenotype. A related, emerging design involves the multiplex analysis of a single library of cells or molecules containing substantial nonrandom genetic variation. In such experiments, the population of cells or molecules is subjected to a single functional assay, and sequencing is used as a readout to reveal the relative activities of individual members of the library, each containing specific mutations. Recent examples of experiments in this vein include the massively parallel functional analysis of regulatory DNA^{93,94,96}, protein domains⁹⁵ and catalytic RNA¹⁰¹, all of which implemented high-density mutagenesis to achieve residue-by-residue perturbation of specific sequences. A related approach is to use multiplex functional assays to efficiently screen complex libraries in which individual cells contain single-gene knockouts^{90–92} or overexpress random genes¹⁰². Some of these methods rely on direct sequencing of the mutagenic event, whereas others require the introduction of synthetic 'barcodes' to capture this information⁹³. Related methods are also enabling more complex explorations of the functional landscape via multiplex assays, for example, 'designer' regulatory elements¹⁰³, fusion-protein libraries¹⁰⁴, and the discovery of physical¹⁰⁵ and genetic^{106,107} interactions.

Protocols for sequencing-based experiments

Sequencing protocols transform one or more cell populations defined by an experimental design into nucleic acids suitable for analysis at the molecular level by a sequencer (Fig. 2b). The conventional approach is to simply isolate DNA or RNA and construct a sequencing-compatible shotgun fragment library, that is, DNA-Seq or RNA-Seq. New protocols target specific subsets of nucleic acids. The first aspect of targeting is the enrichment of specific cells of interest from a heterogeneous cell population. Effective techniques for isolating subsets of cells include gross dissection, flow cytometry and laser-capture microdissection, and are

dependent on the extent to which one can anatomically, molecularly or histologically delineate the cell type(s) of interest. For model organisms, these approaches can be facilitated by genetic manipulation to molecularly mark specific cell type(s). The second aspect of targeting is the extraction of desired subsets of DNA or RNA. The latter can be achieved by targeting the nucleic acids directly (based on primary sequence or accessibility), indirectly (by targeting neighboring molecular entities) or through modification (to capture noncanonical bases). Concurrently with targeting or after targeting, nucleic acids must be converted to a sequencing library, that is, a population of DNA fragments flanked by platform-specific adaptors. At various steps, the addition of sequence 'tags' can allow one to capture additional information (for example, sample indexing or molecular tagging).

Targeting nucleic acids directly. For both DNA and RNA, targeting methods usually achieve specificity through some combination of complementarity-mediated or otherwise specific hybridization, polymerization, ligation and/or cleavage. For DNA, methods for sequence-specific enrichment include standard PCR, multiplex PCR, molecular inversion probes¹⁰⁸ (J.S. and colleagues), selective circularization¹⁰⁹ and hybrid capture^{110,111}. A somewhat distinct category of DNA targeting is to use endonuclease digestion, for example, for reduced representation¹¹², or to define chromatin accessibility by DNase I hypersensitivity¹¹³. For RNA, one is usually interested in a particular subpopulation, such as mRNAs or small RNAs. For example, mRNAs can be enriched by poly(A)-mediated reverse transcription, oligo(dT) hybridization, 'not-so-random' amplification¹¹⁴ or BrdU incorporation (for recently synthesized mRNA). For RNA, preferred methods preserve strand information¹¹⁵, for example, by orientation-specific adaptor ligation, by the ordered incorporation of adaptors during cDNA synthesis or by strand-specific degradation after cDNA synthesis. Other RNA targeting methods are analogous to DNA-targeting methods, for example, reverse transcription-PCR of a specific target. A type of targeting aimed at capturing a different type of information, namely RNA secondary structure, involves digestion with one or more RNases⁴². The negative selection of nucleic acids is also possible, that is, enrichment via the subtraction of undesired material. This includes 'footprinting' techniques in which the target material is protected from nuclease activity, for example, by the presence of bound protein or by single-stranded or double-stranded status. Negative selection can also be accomplished by 'subtractive' hybrid capture, in which DNA or RNA sequences that bind a collection of 'bait' probes are removed.

Targeting nucleic acids indirectly. The alternative to direct targeting of nucleic acids is their indirect purification based on proximity to other molecular entities, for example, specific proteins or other nucleic acids. Such experiments usually begin with a cross-linking step; formaldehyde and UV light are the most common cross-linkers, but dimethyl suberimidate (DMS), dimethyl adipimidate (DMA), glutaraldehyde, bis(sulfosuccinimidyl) suberate (BS3), spermine or spermidine and 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDAC) are alternatives. The choice of cross-linking agent is governed by the types of cross-links desired (for example, DNA-DNA, DNA-protein, RNA-protein and protein-protein), the tendency to damage substrates of interest and compatibility with downstream steps. The next step is usually immunoprecipitation, which enables extraction of nucleic acids of interest by exploiting their proximity to proteins of interest or to particular histone modifications, for example, the ChIP-Seq protocol³⁵. More recently, a new protocol has been emerging that exploits the power of nucleic acid proximity ligation. In these methods, ligation is used to extract spatially co-localized nucleic acids, for example, to explore chromosome interactions in cells^{71–73}.

Modifying nucleic acids to capture additional information. Both DNA and RNA molecules, in their *in vivo* context, can contain additional information beyond their four canonical bases. Recent work has explored an increasingly large collection of nucleotide modifications that are present in genomic DNA. A common approach to identifying such marks is to transform the four-base sequence of the DNA itself to encode the modification of interest. These techniques include bisulfite treatment (to detect cytosine methylation)³⁴, and use of T4 bacteriophage β -glucosyltransferase and Huisgen cycloaddition (which is specific for 5-hydroxymethylcytosine)¹¹⁶. Post-transcriptional modifications of RNA might be detectable by identifying the characteristic error signatures that they cause in sequencing data¹¹⁷. Another creative example of this protocol is the use of specific polymerase error signatures secondary to cross-linking events to identify the precise RNA nucleotide involved in RNA-protein interactions¹¹⁸.

Library construction. Before sequencing, nucleic acids must be converted to a population of DNA fragments flanked by sequencing platform-specific adaptors. If this does not happen as a part of nucleic-acid targeting, it can be done afterward by any of a variety of methods for the *in vitro* construction of complex, shotgun sequencing libraries. Most common are 'fragment libraries', usually generated by random fragmentation (mechanical, chemical or enzymatic) followed by ligation of universal adaptor sequences and (optionally¹¹⁹) PCR amplification. A more recently developed alternative uses a hyperactive derivative of the Tn5 transposase to catalyze *in vitro* integration of the universal adaptor sequences into target DNA at a high density, usually followed by amplification¹²⁰ (J.S. and colleagues). The resulting technique is faster, simpler and requires less input material. Of course, all methods that use amplification must contend with G+C bias and other sequence biases, although extensive efforts have been made to discover how such biases can be minimized¹²¹. PCR-free library preparation¹¹⁹ reduces sequence bias, as do sequencing technologies in which there is no amplification at any stage, for example, the Pacific Biosciences RS (Table 2)¹²².

Sample indexing or molecular tagging. The power of high-throughput sequencing has made it possible to do more than one experiment at a time, and an additional class of protocols enables many experiments to be efficiently multiplexed on a single sequencing lane. This is generally implemented by appending a synthetic index or barcode subsequence to all molecules in a given sequencing library, such that concurrent sequencing of the index can be used to assign reads *in silico* to the specific libraries from which they derived. But synthetic tags are proving to be increasingly useful in other contexts—for example, the tagging of individual molecules in subassembly¹²³ (J.S. and colleagues), wherein the grouping of reads derived from the same nucleic acid enables more accurate quantification, robust error-correction and increased effective read length; the tagging of synthetic variants in synthetic saturation mutagenesis⁹³ (J.S. and colleagues), wherein the synthetic tag is used as the functional readout; and the still unrealized possibility of associating tags with individual cells, to facilitate the ascertainment of genetic or epigenetic variability at single-cell resolution (Table 3).

Sequencing metrics

Although the conventional emphasis in the sequencing technology development field has been on 'price per sequenced nucleotide', costs have dropped to a point where other differentiators of specific technologies are increasingly relevant in a way that relates to the precise sequencing application (Table 2). The cost per base remains most important for large-scale resequencing projects, for example, sequencing large numbers of human genomes; the Illumina HiSeq is currently the most




Figure 3 How we are getting there: a subway map of sequencing technology. Despite the disparate goals of different sequencing experiments, the great variety of sequencing experiments is a result of distinct combinations of a relatively small set of core techniques, which are represented as open circles or 'stations'. Like subway lines, individual sequencing experiments move from station to station, until they ultimately arrive at a common terminal: DNA sequencing. For example, the initial demonstration of Hi-C⁷¹ was a comparative experiment that progressed through cell culture, cross-linking, proximity ligation, mechanical shearing, affinity purification, adaptor ligation and PCR amplification, before finally arriving at sequencing. Other examples shown correspond to sequencing applications in **Table 1**. For visual clarity, not all stations and routes are shown. New routes are being added regularly. TRAP, translating ribosome affinity purification.

be necessary to adequately ascertain single-nucleotide polymorphisms in an individual human genome, but with imputation one can get away with as little as $2\times$ coverage per sample, albeit with tradeoffs with respect to rare and private variants¹²⁴. For the transcriptome, <10 million reads may be sufficient for quantifying 80% of transcripts, but accurately quantifying alternative splicing in a similar number

of transcripts would require >200 million reads¹²⁵. Provided one is performing a sufficient volume of sequencing, sample indexing and pooling can allow one to maximize the value of individual sequencing runs in a way that is matched to the goals of the experiment.

However, cost per base and cost per read are not always the most important metrics. Technologies delivering better contiguity may be particularly relevant to applications such as *de novo* genome assembly or where local haplotype information is key, even when the cost per base is higher than that with other technologies. For example, despite the rela-

widely used instrument for such applications. For applications reliant on tag counting; for example, quantifying epigenetic phenomena via RNA-Seq or ChIP-Seq, the cost per read is more relevant than the cost per base. However, this is well correlated with the cost per base, provided that the read length is sufficient for accurate placement of reads to a reference genome.

There is usually an optimal tradeoff between the number of samples processed and the number of reads per sample that is highly dependent on the context of the experiment. For example, 30-fold coverage may

Table 3 What is next for next-generation DNA sequencing?

'End-to-end' genome assembly or resequencing ¹³³	Complete <i>de novo</i> assemblies are rare, and a substantial fraction of the human genome remains unfinished. Furthermore, there are particular regions as well as particular types of variation that are poorly detected owing to the limitations of current technology and algorithms.
Sequencing of nucleic acids within intact cells ¹³⁴	<i>In situ</i> sequencing may enable applications directed at both DNA, for example, sequencing mitochondrial genomes or tumor genomes within single cells, and RNA, for example, massively parallel characterization of mRNA within single cells to quantify expression or assess subcellular localization.
Multiplex, single cell genomes, epigenomes and transcriptomes ¹³⁵	The single-cell analysis of genomes and transcriptomes (but not yet epigenomes) is increasingly possible. Ideally this would not require individually isolating cells for processing.
Massively parallel assessment of synthetic double mutants ¹³⁶	Large-scale analysis of double mutants can reveal functional relationships between genes, but double mutants are currently phenotyped one by one.
Massively parallel discovery of protein-protein interactions ¹³⁷	The application of next-generation sequencing in the context of high-throughput interactome mapping (for example, yeast two-hybrid screens) will require methods that capture pairings of constructs expressing interacting products within individual cells, ideally in some massively multiplex way.
Quantitatively assaying cell-signaling cascades ¹³⁸	Sequence-based reporters, that is, expressed barcode tags, can potentially be used to quantitatively monitor diverse aspects of cellular signaling in the context of a single cell.
Developmental fate-mapping ¹³⁹	Sequencing can potentially be applied to enable the massively parallel assessment of cell lineage during the development of complex multicellular organisms.
Neuronal connectivity mapping ¹⁴⁰	For example, 'rainbow' methods that use Cre-lox recombination to drive stochastic expression of fluorescent reporters potentially could be rendered more powerful by instead driving stochastic expression of mRNAs that were interrogated by <i>in situ</i> sequencing.
Massively parallel sequencing of polypeptides and post-translational modifications ⁵⁰	Although translation can be interrogated with ribosome profiling ⁴⁸ , we would ideally want to directly sequence polypeptides and their post-translational modifications in some massively parallel way analogous to next-generation sequencing of nucleic acids.

References are to papers that are motivating or that describe important progress in a particular area.

tively high error rate and cost per base of the PacBio RS, its long reads can be combined with more cheaply generated short reads to facilitate *de novo* assembly of both small and large genomes¹²⁶. Other differentiators may lend themselves to the deployment of DNA sequencing in clinical labs, for example, so-called 'bench-top' sequencers¹²⁷. These include (i) speed: a rapid turnaround time, usually accompanied by some tradeoff with respect to cost per base; (ii) portability: a smaller instrument footprint (ideally, this will eventually be a hand-held device); (iii) low capital cost: lowering the barrier to entry for small-scale operations; and (iv) granularity: a low cost to perform one sequencing run. Several instruments, most prominently the Ion Torrent PGM and the Illumina MiSeq, were specifically designed to be appealing in these ways. Lastly, there are technologies that aim to find some middle ground between 'bench-top' characteristics and a low cost per base. These include the Ion Torrent Proton instrument as well as the HiSeq 2500 upgrade.

Future directions

A limited number of molecular and biochemical 'building blocks' have given rise to an extraordinary range of sequencing applications (Table 1). An analogy we introduce in this Review is a subway map, in which diverse routes (experiments) travel between stations (core techniques or building blocks) in myriad patterns (Fig. 3). Eventually, all the trains arrive at the hub: DNA sequencing.

Surveying the 'subway map' of present-day sequencing experiments provokes two observations. First, there are usually multiple routes for accomplishing the same task. For instance, DNA methylation can be mapped in a population of cells either by positive selection (capturing methylated DNA using the methyl-cytosine-binding domain of MeCP2), by negative selection (digesting with a methylation-sensitive restriction enzyme) or by direct transformation (bisulfite treatment). Such alternate pathways to the same end are inevitably differentiated by a variety of factors, such as comprehensiveness, cost, ease of implementation in a research or clinical setting, input requirements and compatibility with other protocols (for example, targeted capture). In designing a sequencing experiment, one should carefully consider these differentiating factors and ask whether a particular approach has advantages specific to one's system. More generally, studies that systematically compare diverse protocols, for example, the many approaches for strand-specific RNA-Seq¹¹², are extremely valuable to the community.

Second, new protocols tend to emerge through the reuse of existing techniques in new contexts. New building blocks are occasionally introduced. But more often than not, new sequencing applications simply borrow from other sequencing applications or from other existing methods. An example of a new technique emerging through such mixing and matching is the recently described use of oxidation mediated by Tet proteins in combination with beta-glucosyltransferase (bGT)¹¹⁵ and bisulfite treatment³⁴ to distinguish 5-hydroxymethylcytosines (5hmC) from 5-methylcytosines (5mC) genome-wide and at base-pair resolution¹²⁸.

Given the remarkable proliferation of high-impact applications of next-generation DNA sequencing in the space of just a few years, we should be optimistic that additional applications—even particularly challenging applications such as those suggested in Table 3—are achievable with sufficient innovation and effort. The subway map analogy suggests that the development of new applications is likely to be best supported by a broad knowledge of existing and emerging sequencing protocols as well as a willingness to delve into the past 50 years of methods development in biochemistry and molecular biology. These sources effectively provide a toolbox that can be drawn on when evaluating potential routes to support new applications. For example, for any cellular phenomenon of interest, are there existing methods (or

combinations of existing methods) that allow it to be coupled to nucleic acid sequence? In addition to actual protocols, there are also concepts that can be reapplied in new contexts. For example, 'tagging' is a general concept that can be applied to molecules, libraries, variants, cells, lineages or organisms. Although challenging, the development of new sequencing applications can be broadly impactful, in some cases opening up entirely new scientific territory to exploration.

Conclusions

The rapid maturation of massively parallel sequencing technology has been accompanied by a proliferation of exciting applications, each of which originated with an investigator asking: 'can we solve this problem through sequencing?' Sequencing is emerging as a ubiquitous, digital 'readout' for the deep, comprehensive exploration of genetics, molecular biology and cellular biophysics. In this Review, we attempted to develop a conceptual framework to describe this panoply of scientific applications as well as the underlying technical protocols that make them possible.

Though truly novel core techniques emerge from time-to-time, it is clear that most new sequencing applications have resulted from efforts to combine the building blocks of existing designs and protocols in different ways. We fully expect this trend to continue, as 'recombination' of these building blocks drives sequencing in new directions (Table 3). Like the cells that they study, biologists have learned to deploy a finite range of tools to meet an extraordinary array of challenges.

ACKNOWLEDGMENTS

We thank L. Solomon and L. Gaffney of the Broad Institute for assistance with the design and preparation of figures; B. Wong and S. Arbesman for input on figure design; A.P. Aiden for valuable comments; and members of the Shendure lab and of the Laboratory at Large for discussions.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Published online at <http://www.nature.com/doi/10.1038/nbt.2421>.

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

- Shendure, J. *et al.* Accurate multiplex polony sequencing of an evolved bacterial genome. *Science* **309**, 1728–1732 (2005).
- Margulies, M. *et al.* Genome sequencing in microfabricated high-density picolitre reactors. *Nature* **437**, 376–380 (2005).
- Shendure, J. & Ji, H. Next-generation DNA sequencing. *Nat. Biotechnol.* **26**, 1135–1145 (2008).
- Wetterstrand, K.A. DNA sequencing costs: data from the NHGRI large-scale genome sequencing program. <http://www.genome.gov/sequencingcosts/>. Accessed 1 October 2012.
- Shendure, J., Mitra, R.D., Varma, C. & Church, G.M. Advanced sequencing technologies: methods and goals. *Nat. Rev. Genet.* **5**, 335–344 (2004).
- Fuller, C.W. *et al.* The challenges of sequencing by synthesis. *Nat. Biotechnol.* **27**, 1013–1023 (2009).
- Branton, D. *et al.* The potential and challenges of nanopore sequencing. *Nat. Biotechnol.* **26**, 1146–1153 (2008).
- Metzker, M.L. Sequencing technologies—the next generation. *Nat. Rev. Genet.* **11**, 31–46 (2010).
- Lindblad-Toh, K. *et al.* A high-resolution map of human evolutionary constraint using 29 mammals. *Nature* **478**, 476–482 (2011).
- Genome 10K Community of Scientists. Genome 10K: a proposal to obtain whole-genome sequence for 10,000 vertebrate species. *J. Hered.* **100**, 659–674 (2009).
- Pevzner, P.A., Tang, H. & Waterman, M.S. An Eulerian path approach to DNA fragment assembly. *Proc. Natl. Acad. Sci. USA* **98**, 9748–9753 (2001).
- Gnerre, S. *et al.* High-quality draft assemblies of mammalian genomes from massively parallel sequence data. *Proc. Natl. Acad. Sci. USA* **108**, 1513–1518 (2011).
- Alkan, C., Sajjadian, S. & Eichler, E.E. Limitations of next-generation genome sequence assembly. *Nat. Methods* **8**, 61–65 (2011).
- Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics* **26**, 589–595 (2010).
- Bentley, D.R. *et al.* Accurate whole human genome sequencing using reversible terminator chemistry. *Nature* **456**, 53–59 (2008).
- Kitzman, J.O. *et al.* Haplotype-resolved genome sequencing of a Gujarati Indian individual. *Nat. Biotechnol.* **29**, 59–63 (2011).
- Peters, B.A. *et al.* Accurate whole-genome sequencing and haplotyping from 10 to 20 human cells. *Nature* **487**, 190–195 (2012).

18. Fan, H.C., Wang, J., Potanina, A. & Quake, S.R. Whole-genome molecular haplotyping of single cells. *Nat. Biotechnol.* **29**, 51–57 (2011).
19. Ma, L. *et al.* Direct determination of molecular haplotypes by chromosome microdissection. *Nat. Methods* **7**, 299–301 (2010).
20. Ng, S.B. *et al.* Targeted capture and massively parallel sequencing of 12 human exomes. *Nature* **461**, 272–276 (2009).
21. Choi, M. *et al.* Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. *Proc. Natl. Acad. Sci. USA* **106**, 19096–19101 (2009).
22. Vissers, L.E. *et al.* A *de novo* paradigm for mental retardation. *Nat. Genet.* **42**, 1109–1112 (2010).
23. O’Roak, B.J. *et al.* Exome sequencing in sporadic autism spectrum disorders identifies severe *de novo* mutations. *Nat. Genet.* **43**, 585–589 (2011).
24. Girard, S.L. *et al.* Increased exonic *de novo* mutation rate in individuals with schizophrenia. *Nat. Genet.* **43**, 860–863 (2011).
25. Manolio, T.A. *et al.* Finding the missing heritability of complex diseases. *Nature* **461**, 747–753 (2009).
26. Kohane, I.S. & Shendure, J. What’s a genome worth? *Sci. Transl. Med.* **4**, 133fs113 (2012).
27. Roberts, N.J. *et al.* The predictive capacity of personal genome sequencing. *Sci. Transl. Med.* **4**, 133ra158 (2012).
28. Worthey, E.A. *et al.* Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. *Genet. Med.* **13**, 255–262 (2011).
29. Bainbridge, M.N. *et al.* Whole-genome sequencing for optimized patient management. *Sci. Transl. Med.* **3**, 87re83 (2011).
30. Bell, C.J. *et al.* Carrier testing for severe childhood recessive diseases by next-generation sequencing. *Sci. Transl. Med.* **3**, 65ra64 (2011).
31. Fan, H.C., Blumenfeld, Y.J., Chitkara, U., Hudgins, L. & Quake, S.R. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. *Proc. Natl. Acad. Sci. USA* **105**, 16266–16271 (2008).
32. Chiu, R.W. *et al.* Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. *Proc. Natl. Acad. Sci. USA* **105**, 20458–20463 (2008).
33. Kitzman, J.O. *et al.* Noninvasive whole-genome sequencing of a human fetus. *Sci. Transl. Med.* **4**, 137ra176 (2012).
34. Lister, R. *et al.* Human DNA methylomes at base resolution show widespread epigenomic differences. *Nature* **462**, 315–322 (2009).
35. Johnson, D.S., Mortazavi, A., Myers, R.M. & Wold, B. Genome-wide mapping of *in vivo* protein-DNA interactions. *Science* **316**, 1497–1502 (2007).
36. Barski, A. *et al.* High-resolution profiling of histone methylations in the human genome. *Cell* **129**, 823–837 (2007).
37. Hesselberth, J.R. *et al.* Global mapping of protein-DNA interactions *in vivo* by digital genomic footprinting. *Nat. Methods* **6**, 283–289 (2009).
38. Lickwar, C.R., Mueller, F., Hanlon, S.E., McNally, J.G. & Lieb, J.D. Genome-wide protein-DNA binding dynamics suggest a molecular clutch for transcription factor function. *Nature* **484**, 251–255 (2012).
39. Mortazavi, A., Williams, B.A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nat. Methods* **5**, 621–628 (2008).
40. Montgomery, S.B. *et al.* Transcriptome genetics using second generation sequencing in a Caucasian population. *Nature* **464**, 773–777 (2010).
41. Churchman, L.S. & Weissman, J.S. Nascent transcript sequencing visualizes transcription at nucleotide resolution. *Nature* **469**, 368–373 (2011).
42. Kertesz, M. *et al.* Genome-wide measurement of RNA secondary structure in yeast. *Nature* **467**, 103–107 (2010).
43. Wang, E.T. *et al.* Alternative isoform regulation in human tissue transcriptomes. *Nature* **456**, 470–476 (2008).
44. Li, J.B. *et al.* Genome-wide identification of human RNA editing sites by parallel DNA capturing and sequencing. *Science* **324**, 1210–1213 (2009).
45. Sanford, J.R. *et al.* Splicing factor SFRS1 recognizes a functionally diverse landscape of RNA transcripts. *Genome Res.* **19**, 381–394 (2009).
46. Licatalosi, D.D. *et al.* HITS-CLIP yields genome-wide insights into brain alternative RNA processing. *Nature* **456**, 464–469 (2008).
47. Rabani, M. *et al.* Metabolic labeling of RNA uncovers principles of RNA production and degradation dynamics in mammalian cells. *Nat. Biotechnol.* **29**, 436–442 (2011).
48. Ingolia, N.T., Ghaemmaghami, S., Newman, J.R. & Weissman, J.S. Genome-wide analysis *in vivo* of translation with nucleotide resolution using ribosome profiling. *Science* **324**, 218–223 (2009).
49. Howorka, S. & Siwy, Z.S. Nanopores as protein sensors. *Nat. Biotechnol.* **30**, 506–507 (2012).
50. Tessler, L.A., Reifenger, J.G. & Mitra, R.D. Protein quantification in complex mixtures by solid phase single-molecule counting. *Anal. Chem.* **81**, 7141–7148 (2009).
51. Boyd, S.D. *et al.* Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. *Sci. Transl. Med.* **1**, 12ra23 (2009).
52. Freeman, J.D., Warren, R.L., Webb, J.R., Nelson, B.H. & Holt, R.A. Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing. *Genome Res.* **19**, 1817–1824 (2009).
53. Wang, C. *et al.* High throughput sequencing reveals a complex pattern of dynamic interrelationships among human T cell subsets. *Proc. Natl. Acad. Sci. USA* **107**, 1518–1523 (2010).
54. Robins, H.S. *et al.* Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. *Blood* **114**, 4099–4107 (2009).
55. Price, D.A. *et al.* Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection. *J. Exp. Med.* **206**, 923–936 (2009).
56. Hanahan, D. & Weinberg, R.A. Hallmarks of cancer: the next generation. *Cell* **144**, 646–674 (2011).
57. Ley, T.J. *et al.* DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. *Nature* **456**, 66–72 (2008).
58. Welch, J.S. *et al.* Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. *J. Am. Med. Assoc.* **305**, 1577–1584 (2011).
59. Jones, S.J. *et al.* Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. *Genome Biol.* **11**, R82 (2010).
60. Leary, R.J. *et al.* Development of personalized tumor biomarkers using massively parallel sequencing. *Sci. Transl. Med.* **2**, 20ra14 (2010).
61. Li, M. *et al.* Sensitive digital quantification of DNA methylation in clinical samples. *Nat. Biotechnol.* **27**, 858–863 (2009).
62. Navin, N. *et al.* Tumour evolution inferred by single-cell sequencing. *Nature* **472**, 90–94 (2011).
63. Grice, E.A. *et al.* Topographical and temporal diversity of the human skin microbiome. *Science* **324**, 1190–1192 (2009).
64. Gill, S.R. *et al.* Metagenomic analysis of the human distal gut microbiome. *Science* **312**, 1355–1359 (2006).
65. Gardy, J.L. *et al.* Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. *N. Engl. J. Med.* **364**, 730–739 (2011).
66. Harris, S.R. *et al.* Evolution of MRSA during hospital transmission and intercontinental spread. *Science* **327**, 469–474 (2010).
67. Codoner, F.M. *et al.* Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects. *PLoS ONE* **6**, e19461 (2011).
68. Zagordi, O., Klein, R., Daumer, M. & Beerenwinkel, N. Error correction of next-generation sequencing data and reliable estimation of HIV quasispecies. *Nucleic Acids Res.* **38**, 7400–7409 (2010).
69. Turnbaugh, P.J. *et al.* A core gut microbiome in obese and lean twins. *Nature* **457**, 480–484 (2009).
70. Cullen, K.E., Kladde, M.P. & Seyfred, M.A. Interaction between transcription regulatory regions of prolactin chromatin. *Science* **261**, 203–206 (1993).
71. Lieberman-Aiden, E. *et al.* Comprehensive mapping of long-range interactions reveals folding principles of the human genome. *Science* **326**, 289–293 (2009).
72. Duan, Z. *et al.* A three-dimensional model of the yeast genome. *Nature* **465**, 363–367 (2010).
73. Fullwood, M.J. *et al.* An oestrogen-receptor-alpha-bound human chromatin interactome. *Nature* **462**, 58–64 (2009).
74. Berger, M.F. *et al.* The genomic complexity of primary human prostate cancer. *Nature* **470**, 214–220 (2011).
75. Hansen, R.S. *et al.* Sequencing newly replicated DNA reveals widespread plasticity in human replication timing. *Proc. Natl. Acad. Sci. USA* **107**, 139–144 (2010).
76. ENCODE Project Consortium *et al.* Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. *Nature* **447**, 799–816 (2007).
77. Gerstein, M.B. *et al.* Integrative analysis of the *Caenorhabditis elegans* genome by the modENCODE project. *Science* **330**, 1775–1787 (2010).
78. Gore, A. *et al.* Somatic coding mutations in human induced pluripotent stem cells. *Nature* **471**, 63–67 (2011).
79. Baranzini, S.E. *et al.* Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. *Nature* **464**, 1351–1356 (2010).
80. Green, R.E. *et al.* A draft sequence of the Neandertal genome. *Science* **328**, 710–722 (2010).
81. Schacherer, J., Shapiro, J.A., Ruderfer, D.M. & Kruglyak, L. Comprehensive polymorphism survey elucidates population structure of *Saccharomyces cerevisiae*. *Nature* **458**, 342–345 (2009).
82. Hess, M. *et al.* Metagenomic discovery of biomass-degrading genes and genomes from cow rumen. *Science* **331**, 463–467 (2011).
83. Kao, K.C. & Sherlock, G. Molecular characterization of clonal interference during adaptive evolution in asexual populations of *Saccharomyces cerevisiae*. *Nat. Genet.* **40**, 1499–1504 (2008).
84. Gresham, D. *et al.* The repertoire and dynamics of evolutionary adaptations to controlled nutrient-limited environments in yeast. *PLoS Genet.* **4**, e1000303 (2008).
85. Andries, K. *et al.* A diarylquinoline drug active on the ATP synthase of *Mycobacterium tuberculosis*. *Science* **307**, 223–227 (2005).
86. Logan, A.C. *et al.* High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. *Proc. Natl. Acad. Sci. USA* **108**, 21194–21199 (2011).
87. Bassik, M.C. *et al.* Rapid creation and quantitative monitoring of high coverage shRNA libraries. *Nat. Methods* **6**, 443–445 (2009).
88. Boyden, E.S., Zhang, F., Bamberg, E., Nagel, G. & Deisseroth, K. Millisecond-timescale, genetically targeted optical control of neural activity. *Nat. Neurosci.* **8**, 1263–1268 (2005).
89. Amit, I. *et al.* Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. *Science* **326**, 257–263 (2009).
90. Goodman, A.L. *et al.* Identifying genetic determinants needed to establish a human gut symbiont in its habitat. *Cell Host Microbe* **6**, 279–289 (2009).
91. Gallagher, L.A., Shendure, J. & Manoil, C. Genome-scale identification of resistance functions in *Pseudomonas aeruginosa* using Tn-seq. *MBio* **2**, e00315–e00310 (2011).
92. Carrette, J.E. *et al.* Global gene disruption in human cells to assign genes to phenotypes by deep sequencing. *Nat. Biotechnol.* **29**, 542–546 (2011).

93. Patwardhan, R.P. *et al.* High-resolution analysis of DNA regulatory elements by synthetic saturation mutagenesis. *Nat. Biotechnol.* **27**, 1173–1175 (2009).
94. Melnikov, A. *et al.* Systematic dissection and optimization of inducible enhancers in human cells using a massively parallel reporter assay. *Nat. Biotechnol.* **30**, 271–277 (2012).
95. Fowler, D.M. *et al.* High-resolution mapping of protein sequence-function relationships. *Nat. Methods* **7**, 741–746 (2010).
96. Patwardhan, R.P. *et al.* Massively parallel functional dissection of mammalian enhancers *in vivo*. *Nat. Biotechnol.* **30**, 265–270 (2012).
97. Takahashi, K. *et al.* Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* **131**, 861–872 (2007).
98. Stadtfeld, M., Nagaya, M., Utikal, J., Weir, G. & Hochedlinger, K. Induced pluripotent stem cells generated without viral integration. *Science* **322**, 945–949 (2008).
99. Kaji, K. *et al.* Virus-free induction of pluripotency and subsequent excision of reprogramming factors. *Nature* **458**, 771–775 (2009).
100. Yu, J. *et al.* Human induced pluripotent stem cells free of vector and transgene sequences. *Science* **324**, 797–801 (2009).
101. Pitt, J.N. & Ferre-D'Amare, A.R. Rapid construction of empirical RNA fitness landscapes. *Science* **330**, 376–379 (2010).
102. Yu, Z. *et al.* Activators of the glutamate-dependent acid resistance system alleviate deleterious effects of YidC depletion in *Escherichia coli*. *J. Bacteriol.* **193**, 1308–1316 (2011).
103. Gertz, J., Siggia, E.D. & Cohen, B.A. Analysis of combinatorial cis-regulation in synthetic and genomic promoters. *Nature* **457**, 215–218 (2009).
104. Nett, J.H. *et al.* A combinatorial genetic library approach to target heterologous glycosylation enzymes to the endoplasmic reticulum or the Golgi apparatus of *Pichia pastoris*. *Yeast* **28**, 237–252 (2011).
105. Di Niro, R. *et al.* Rapid interactome profiling by massive sequencing. *Nucleic Acids Res.* **38**, e110 (2010).
106. Baryshnikova, A. *et al.* Quantitative analysis of fitness and genetic interactions in yeast on a genome scale. *Nat. Methods* **7**, 1017–1024 (2010).
107. Roguev, A. *et al.* Conservation and rewiring of functional modules revealed by an epistasis map in fission yeast. *Science* **322**, 405–410 (2008).
108. Turner, E.H., Lee, C., Ng, S.B., Nickerson, D.A. & Shendure, J. Massively parallel exon capture and library-free resequencing across 16 genomes. *Nat. Methods* **6**, 315–316 (2009).
109. Dahl, F., Gullberg, M., Stenberg, J., Landegren, U. & Nilsson, M. Multiplex amplification enabled by selective circularization of large sets of genomic DNA fragments. *Nucleic Acids Res.* **33**, e71 (2005).
110. Bashiardes, S. *et al.* Direct genomic selection. *Nat. Methods* **2**, 63–69 (2005).
111. Gnirke, A. *et al.* Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. *Nat. Biotechnol.* **27**, 182–189 (2009).
112. Meissner, A. *et al.* Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. *Nucleic Acids Res.* **33**, 5868–5877 (2005).
113. John, S. *et al.* Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. *Nat. Genet.* **43**, 264–268 (2011).
114. Armour, C.D. *et al.* Digital transcriptome profiling using selective hexamer priming for cDNA synthesis. *Nat. Methods* **6**, 647–649 (2009).
115. Levin, J.Z. *et al.* Comprehensive comparative analysis of strand-specific RNA sequencing methods. *Nat. Methods* **7**, 709–715 (2010).
116. Song, C.X. *et al.* Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. *Nat. Biotechnol.* **29**, 68–72 (2011).
117. Findeiss, S., Langenberger, D., Stadler, P.F. & Hoffmann, S. Traces of post-transcriptional RNA modifications in deep sequencing data. *Biol. Chem.* **392**, 305–313 (2011).
118. Zhang, C. & Darnell, R.B. Mapping *in vivo* protein-RNA interactions at single-nucleotide resolution from HTS-CLIP data. *Nat. Biotechnol.* **29**, 607–614 (2011).
119. Mamanova, L. *et al.* FRT-seq: amplification-free, strand-specific transcriptome sequencing. *Nat. Methods* **7**, 130–132 (2010).
120. Adey, A. *et al.* Rapid, low-input, low-bias construction of shotgun fragment libraries by high-density *in vitro* transposition. *Genome Biol.* **11**, R119 (2010).
121. Aird, D. *et al.* Analyzing and minimizing PCR amplification bias in Illumina sequencing libraries. *Genome Biol.* **12**, R18 (2011).
122. Eid, J. *et al.* Real-time DNA sequencing from single polymerase molecules. *Science* **323**, 133–138 (2009).
123. Hiatt, J.B., Patwardhan, R.P., Turner, E.H., Lee, C. & Shendure, J. Parallel, tag-directed assembly of locally derived short sequence reads. *Nat. Methods* **7**, 119–122 (2010).
124. Li, Y., Willer, C., Sanna, S. & Abecasis, G. Genotype imputation. *Annu. Rev. Genomics Hum. Genet.* **10**, 387–406 (2009).
125. Blencowe, B.J., Ahmad, S. & Lee, L.J. Current-generation high-throughput sequencing: deepening insights into mammalian transcriptomes. *Genes Dev.* **23**, 1379–1386 (2009).
126. Koren, S. *et al.* Hybrid error correction and *de novo* assembly of single-molecule sequencing reads. *Nat. Biotechnol.* **30**, 693–700 (2012).
127. Loman, N.J. *et al.* Performance comparison of benchtop high-throughput sequencing platforms. *Nat. Biotechnol.* **30**, 434–439 (2012).
128. Yu, M. *et al.* Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. *Cell* **149**, 1368–1380 (2012).
129. Deng, J. *et al.* Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. *Nat. Biotechnol.* **27**, 353–360 (2009).
130. Ponts, N. *et al.* Nucleosome landscape and control of transcription in the human malaria parasite. *Genome Res.* **20**, 228–238 (2010).
131. Mikkelsen, T.S. *et al.* Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. *Nature* **448**, 553–560 (2007).
132. Heiman, M. *et al.* A translational profiling approach for the molecular characterization of CNS cell types. *Cell* **135**, 738–748 (2008).
133. Ribeiro, F. *et al.* Finished bacterial genomes from shotgun sequence data. *Genome Res.* Advance online publication 28 September 2012 (doi:10.1101/gr.141515.112).
134. Larsson, C. *et al.* *In situ* genotyping individual DNA molecules by target-primed rolling-circle amplification of padlock probes. *Nat. Methods* **1**, 227–232 (2004).
135. Ramskold, D. *et al.* Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. *Nat. Biotechnol.* **30**, 777–782 (2012).
136. Costanzo, M. *et al.* The genetic landscape of a cell. *Science* **327**, 425–431 (2010).
137. Yu, H. *et al.* Next-generation sequencing to generate interactome datasets. *Nat. Methods* **8**, 478–480 (2011).
138. Botvinnik, A., Wichert, S.P., Fischer, T.M. & Rossner, M.J. Integrated analysis of receptor activation and downstream signaling with EXTassays. *Nat. Methods* **7**, 74–80 (2010).
139. Carlson, C.A. *et al.* Decoding cell lineage from acquired mutations using arbitrary deep sequencing. *Nat. Methods* **9**, 78–80 (2012).
140. Livet, J. *et al.* Transgenic strategies for combinatorial expression of fluorescent proteins in the nervous system. *Nature* **450**, 56–62 (2007).